Results 51 to 60 of about 1,824 (166)

Molecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines

Cancer Science, Volume 117, Issue 6, Page 1623-1634, June 2026.
Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.
Kazue Ito, Noriko Ishida, Shin Ito, Norihisa Shindo, Satoshi Souma, Mai Mochizuki, Haruna Fujimori, Keiichi Tamai, Takayuki Imai, Tomoko Yamazaki, Kazunori Yamaguchi, Kento Sasaki, Yuya Miyakura, Shigekazu Murakami, Yuka Unno, Naoki Asano, Yukinori Asada, Jun Yasuda   +17 more
wiley   +1 more source

Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint [PDF]

Molecular Cancer Therapeutics, 2006
Abstract Spindle poisons such as paclitaxel are widely used as cancer therapeutics. By interfering with microtubule dynamics, paclitaxel induces mitotic arrest and apoptosis. Targeting the kinesin Eg5, which is required for the formation of a bipolar spindle, is a promising therapeutic alternative to drugs that interfere with ...
Gregory M, Chin, Ronald, Herbst
openaire   +2 more sources

The Long Haul: Microtubule Motors as the Essential Supply Line for Neuronal Longevity

Journal of Neurochemistry, Volume 170, Issue 6, June 2026.
To survive a lifetime, neurons depend on a high‐fidelity logistics network powered by microtubule motors. We explore how a broad spectrum of genetic defects in this machinery drive a devastating spectrum of neurodevelopmental and neurodegenerative diseases, including Hereditary Spastic Paraplegia (HSP), Charcot–Marie‐Tooth Type 2 (CMT2), and ...
Emma D. Turner, Alison E. Twelvetrees
wiley   +1 more source

Receptor–Ligand Interaction-Based Virtual Screening for Novel Eg5/Kinesin Spindle Protein Inhibitors

, 2016
Eg5/KSP is a promising mitotic spindle target for drug discovery in cancer chemotherapy and the development of agents against fungal diseases. A range of Eg5 targeting compounds identified by in vitro or cell-based screening is currently in development ...
Ae Nim Pae (806345), Frank Kozielski (1283658), Shanthi Nagarajan (29553), Dimitrios A. Skoufias (173868)   +3 more
core   +1 more source

Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5–Inhibitor Complexes [PDF]

, 2019
Arry-520 is an advanced drug candidate from the Eg5 inhibitor class undergoing clinical evaluation in patients with relapsed or refractory multiple myeloma. Here we show by structural analysis that Arry-520 binds stoichiometrically to the motor domain of
Indorato, R-L, Mackay, SP, Kozielski, F, Skoufias, DA, Haider, S, Talapatra, SK, Lin, F   +6 more
core   +3 more sources

Interplay of RNA m6A/m1A/m5C/m7G/ψ Regulators Predicting the Prognosis of Pancreatic Cancer

FASEB BioAdvances, Volume 8, Issue 5, May 2026.
In this study, we comprehensively analyze the 64 RNA modification regulators, including 24 m6A regulators, 13 m1A regulators, 12 m5C regulators, 9 m7G regulators, and 12 pseudouridine regulators in pancreatic cancer in TCGA, GTEx, and HPA databases. We investigate their RNA and protein expression, their association with patients' clinical significance,
Shiyin Chen, Jiawei Mao, Lin Xu, Linbei Lu, Yajuan Hao   +4 more
wiley   +1 more source

A Nucleolar Stress–Specific p53–miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor NetworkResearch in context

EBioMedicine, 2018
Background: Activation of intrinsic p53 tumor-suppressor (TS) pathways is an important principle underlying cancer chemotherapy. It is necessary to elucidate the precise regulatory mechanisms of these networks to create new treatment strategies. Methods:
Yuko Fujiwara, Motonobu Saito, Ana I. Robles, Momoyo Nishida, Fumitaka Takeshita, Masatoshi Watanabe, Takahiro Ochiya, Jun Yokota, Takashi Kohno, Curtis C. Harris, Naoto Tsuchiya   +10 more
doaj   +1 more source

Cloning, Enzyme Characterization of Recombinant Human Eg5 and the Development of a New Inhibitor

Biological and Pharmaceutical Bulletin, 2008
The microtubule-dependent motor protein Eg5 is essential for the development and function of the mitotic spindle. Now it has become an anti-mitotic drug target in high throughput screening for anticancer dugs in vitro. Here is a protocol for cloning, expression and purification of a human Eg5 that codes for motor and linker domain in Escherichia coli ...
Yang, Lei, Jiang, Cheng, Liu, Fei, You, Qi-Dong, Wu, Wu-Tong   +4 more
openaire   +3 more sources

p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells [PDF]

Cancer Biology & Therapy, 2012
Antimitotics such as taxanes are being considered as alternatives to conventional cisplatin-based chemotherapy in patients with bladder cancer, but the molecular determinants of sensitivity or resistance to these agents in bladder cancer cells have not been defined.
Lauren, Marquis, Mai, Tran, Woonyoung, Choi, I-Ling, Lee, Dennis, Huszar, Arlene, Siefker-Radtke, Colin, Dinney, David J, McConkey   +7 more
openaire   +2 more sources

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, Volume 117, Issue 4, Page 917-928, April 2026.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source